Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: An evaluation from a patient's perspective

Rheumatology

Volumn 47, Issue 2, 2008, Pages 188-193

  Mittendorf, T ^a   Dietz, B ^b   Sterz, R ^b   Cifaldi, M A ^c   Kupper, H ^b   Von Der Shulenburg, J M ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Out of pocket payments; Patient perspective; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE DURATION; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PAIN; PATIENT ATTITUDE; PATIENT TRANSPORT; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; WORK DISABILITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENTS; PLACEBOS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 38649120513     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem317     Document Type: Article

References (37)

1. World Health Organization. The burden of musculoskeletal conditions at the start of the new millennium. Available at: http://whqlibdoc.who-int/ trs/WHO_TRS_919.pdf (4 June 2007. date last accessed).
2. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costa for rheumatoid arthritis: A systematic literature review. Pharmacoeconomics 2005;23:243-57.
3. European Medicines Evaluation Agency. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http://www.emea.eu.int/pdfs/human/ewp/13939104en.pdf (4 June 2007, date last accessed).
4. Food and Drug Administration. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims, draft guidance. Available at: http://www.fda.gov/cber/gdins/ proibl.htm (4 June 2007, date last accessed).
5. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination treatment with adalimumab plus methotroxate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
7. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. van de Putte LBA, Rau R, Burmester GR et al. Sustained 5-year efficacy of adalimumab (HUMIRA®) monotherapy in DMARD-refractory rheumatoid arthritis (RA). Arthritis Rheum 2003;48(Suppl.):S314.
9. Weinblait ME, Keystone EC, Furst DE et al. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 2006;65:753-69.
10. Schiff MH, Burmester GR, Kent JM et al. Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheumatic Dis 2006;65:889-94.
11. Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
12. Bansback N, Regier D, Ara R et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus an tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
13. Mittendorf T, Dietz BM, von der Schulenburg JM et al. Decreased resource utilization during long-term treatment with adalimumab in patients with long-standing RA. Arthritis Rheum 2006;54(Suppl.):S115.
14. Dietz BM, van do Putte LBA, Holtbrugge W et al. Adalimumab (HUMIRA®) monotherapy sustains long-term improvements in fatigue in patients with severe rheumatoid arthritis (RA). Ann Rheum Dis 2005;64(Suppl. III):579.
15. Dietz BM, van de Putte LBA, Holtbrugge W et al. Adalimumab (HUMIRA®) monotherapy provides sustained long-term improvement in health utility in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2005;64(Suppl. III):393.
16. Mittendorf T, Sterz R, von der Schulenburg JM et al. Effects of long-term adalimumab therapy on health utility and fatigue in patients with long-standing, severe rheumatoid arthritis (RA): Results from a 3-year follow-up study. Value Health 2005;8:A30.
17. Mittendorf T, Dietz BM, Sterz R et al. Improvement and long-term maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol 2007, Oct 1; [Epub ahead of print).
18. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority. Arthritis Care Res 2002;47:391-7.
19. Ahlmén M, Nordensklöld U, Archenholtz B et al. Rheumatology outcomes: The patient's perspective. A multicenter focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology 2005;44:105-10.
20. Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis: Interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res 2000;13:11-22.
21. Douglas D, Suurmeijer T, van don Heuvel W et al. Functional disabitity, social support, and depression in rheumatoid arthritis. Qual Life Res 2004;13:1063-6.
22. Listing J, Alten R, Brauer D et al. Importance of psychological well being and disease activity in termination of an initial DMARD therapy. J Rheumatol 1997;24:2097-105.
23. Brouwer W, van Exel J, van den Berg B et al. Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis. Arthritis Rheum 2004;51:570-7.
24. Jacobi CE, van don Berg B, Boshuizen H, Rupp I, Dinant W, van den Bos GA. Dimension-specific burden of caregiving among partners of rheumatoid arthritis patients. Rheumatology 2003:42:1226-33.
25. van den Berg B, Spauwen P. Measurement of informal care an empirical study into the valid measurement of time spent on informal caregiving. Health Econ 2006;15:447-60.
26. Allaire S, Wolfe, F, Niu J, Lavalley M, Michaud K. Work disability and its income effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005;53:603-8.
27. Boonen A. Everyone has the right to work. J Rheumatol 2005;32:571-4.
28. Puolakka K, Kautiainen H, Möttönen T et al. Predictors of productivity loss in early rheumatoid arthritis: A 5 year follow up study. Ann Rheum Dis 2005;64:130-3.
29. de Croon EM, Sluiter JK, Nijssen TF et al. Predictive factors of work disability in rheumatoid arthritis: A systematic literature review. Am Rheum Dis 2004;63:1362-7.
30. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32:721-8.
31. Alexander CG, Caselino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:953-8.
32. Huelsemann JL, Mittendorf T, Merkesdal S. Direct costs related to rheumatoid arthritis: The patient perspective. Ann Rheum Dis 2005;64:1456-61.
33. Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff 2001;20:267-78.
34. Ruof J, Huelsemann JL, Mittendorf T et al. Costs of rheumatold arthritis in Germany: A micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-50.
35. Ruof J, Huelsemann JL, Mittendorf T et al. Patient-reported health care utilization in rheumatoid arthritis: What level of detail is required? Arthritis Rheum 2004;51:774-81.
36. Kirwan JR, Hewlett SE, Nelberg T et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2006;32:2250-56.
37. van Exel NJ, Brouwer WB, van den Berg B, Koopmanschap MA, van den Bos GA. What really matters: An inquiry into the relative importance of dimensions of informal caregiver burden. Clin Rehabil 2004;18:683-93.